Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aspergillosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Aspergillosis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-004554-32 Sponsor Protocol Number: PC_ASP_006 Start Date*: 2022-07-09
    Sponsor Name:Pulmocide Ltd
    Full Title: A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonar...
    Medical condition: Refractory invasive pulmonary aspergillosis (IPA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004988-27 Sponsor Protocol Number: FG-463-21-20 Start Date*: 2006-07-27
    Sponsor Name:Astellas Pharma BV
    Full Title: A PHASE II, MULTICENTRE, RANDOMISED, OPEN-LABEL, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MICAFUNGIN SALVAGE MONO THERAPY VERSUS ACTIVE CONTROL INTRAVENOUS SALVAGE MONO THE...
    Medical condition: Patients with haematopoietic stem cell transplantation (HSCT), acute leukaemia, myelodysplastic syndrome (MDS) and with proven (probable only in case of pulmonary aspergillosis) invasive aspergillo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001936-30 Sponsor Protocol Number: Uni-Koeln-687 Start Date*: 2006-09-21
    Sponsor Name:Universität zu Köln
    Full Title: A phase II dose escalation study of caspofungin in patients with invasive aspergillosis
    Medical condition: proven or probable aspergillosis in immunocompromised patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003488 Aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003921-40 Sponsor Protocol Number: 2016IF002 Start Date*: 2017-07-21
    Sponsor Name:University Hospital of South Manchester NHS Foundation Trust
    Full Title: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis
    Medical condition: Chronic Pulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000154164 10003488 Aspergillosis LLT
    20.0 100000015649 10003493 Aspergillus fumigatus bronchopulmonary infection LLT
    20.0 100000154164 10003494 Aspergillus fumigatus infection LLT
    20.0 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 100000015649 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002445-20 Sponsor Protocol Number: A8851009 Start Date*: 2007-11-01
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS...
    Medical condition: INVASIVE ASPERGILLOSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003488 Aspergillosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Ongoing) FR (Completed) GB (Completed) ES (Completed) IT (Completed) DE (Completed) CZ (Completed) BE (Completed) PT (Completed) GR (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006648-23 Sponsor Protocol Number: CIGE025A2437 Start Date*: 2008-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis
    Medical condition: Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung LLT
    9.1 10000244 ABPA LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) IE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002944-90 Sponsor Protocol Number: EORTC 65041 Start Date*: 2005-07-26
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin (CASP) in the First-line Treatment of probable and proven Invasive Aspergillosis 'IA) in Patients with Hematol...
    Medical condition: Invasive aspergillosis in patients with haematological malignancies (HM)/autologous Hematopoietic Stem Cell Transplantation (HSCT) – group A- and patients with allogeneic HSCT transplantation – gro...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003488 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001841-16 Sponsor Protocol Number: VOCARE-07-01 Start Date*: 2008-09-17
    Sponsor Name:Melchor Riera Jaume
    Full Title: ENSAYO CLÍNICO ALEATORIZADO Y CONTROLADO DE VORICONAZOL FRENTE A PLACEBO EN LA PROFILAXIS DE ASPERGILOSIS PULMONAR EN PACIENTES COLONIZADOS CON PATOLOGÍA RESPIRATORIA CRÓNICA (ESTUDIO VOCARE)
    Medical condition: Aspergilosis pulmonar invasiva
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005275-10 Sponsor Protocol Number: A1501080 Start Date*: 2009-03-24
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS...
    Medical condition: Treatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003488 Aspergillosis LLT
    9.1 10051919 Fusarium infection LLT
    9.1 10059045 Scedosporium infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) DE (Completed) BG (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003270-14 Sponsor Protocol Number: POSA-FLU Start Date*: 2017-11-06
    Sponsor Name:UZ Leuven
    Full Title: A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of Posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patients
    Medical condition: invasive aspergillosis in critically ill patients with influenza pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021231-14 Sponsor Protocol Number: A1501095 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVA...
    Medical condition: Primary therapy of invasive aspergillosis (IA) in pediatric subjects aged 2 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003488 Aspergillosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) FR (Ongoing) NL (Ongoing) DK (Prematurely Ended) PL (Completed) DE (Prematurely Ended) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-000499-32 Sponsor Protocol Number: FSJD-ABELNEB-2010 Start Date*: 2011-09-29
    Sponsor Name:FUNDACIÓ SANT JOAN DE DEU
    Full Title: A PHASE II CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF AMPHOTERICIN B LIPID COMPLEX (ABELCET®) FOR THE PROPHYLAXIS OF INVASIVE PULMONARY ASPERGILLOSIS DURING PROLONGED NEUTROPENIA IN ...
    Medical condition: Invasive pulmonary aspergillosis in patients with acute myeloblastic or lymphoblastic leukaemia.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000972-14 Sponsor Protocol Number: CPAAARI Start Date*: 2018-07-04
    Sponsor Name:CHU DE POITIERS
    Full Title: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pu...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002289-33 Sponsor Protocol Number: 601-0018 Start Date*: 2023-02-01
    Sponsor Name:Pulmatrix, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on S...
    Medical condition: Allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.1 100000004862 10001707 Allergic bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000627-40 Sponsor Protocol Number: IA-DUET Start Date*: 2020-12-28
    Sponsor Name:Erasmus MC
    Full Title: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002949-11 Sponsor Protocol Number: 601-0014 Start Date*: 2019-08-05
    Sponsor Name:Pulmatrix, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PU...
    Medical condition: Asthma with Allergic Bronchopulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10006474 Bronchopulmonary aspergillosis allergic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003868-59 Sponsor Protocol Number: WSA-CS-004 Start Date*: 2011-05-12
    Sponsor Name:Astellas Global Pharma Development, Inc.
    Full Title: A phase III, double blind, randomized study to evaluate safety and efficacy of BAL8557 versus voriconazole for primary treatment of invasive fungal disease caused by Apsergillus species or other fi...
    Medical condition: Invasive fungal disease caused by Aspergillus species or other filamentous fungi.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10003488 Aspergillosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006633-19 Sponsor Protocol Number: TFF-V2-001 Start Date*: 2022-08-02
    Sponsor Name:TFF Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Randomized, Safety, Pharmacokinetic, and Efficacy Study of Voriconazole Inhalation Powder Compared to Oral Voriconazole Tablets in Subjects with Acute Invasive Pulmonary Aspe...
    Medical condition: Invasive pulmonary aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002619-24 Sponsor Protocol Number: R668-ABPA-1923 Start Date*: 2020-09-08
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis
    Medical condition: Allergic bronchopulmonary aspergillosis (ABPA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10001707 Allergic bronchopulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) FR (Prematurely Ended) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003435-11 Sponsor Protocol Number: VL2397-201 Start Date*: 2018-08-14
    Sponsor Name:Vical Incorporated
    Full Title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Immunocompromised Adults
    Medical condition: Invasive Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10051597 Cerebral aspergillosis PT
    20.1 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 10021881 - Infections and infestations 10003490 Aspergillosis pharyngeal LLT
    20.1 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    20.0 10021881 - Infections and infestations 10059259 Pulmonary aspergillosis LLT
    20.0 10021881 - Infections and infestations 10003488 Aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 21:57:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA